MarketingRx roundup: Amgen, Lilly, Biohaven migraine brand recall low, study says; Novartis looks to remake drug launch model
Forget the migraine marketing brand wars. When it comes to patients, many can’t even name one despite substantial advertising efforts, according to a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
